Revenue
2019
2020
2021
2022
2023
2024
2025
SOPHiA GENETICS SA (SOPH)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $77.3M | $65.2M | $62.4M | $47.6M | $40.5M | $28.4M | $25.4M |
| Gross profit | $52.1M | $43.9M | $42.9M | $31.3M | $25.2M | $17.7M | $17.8M |
| Research & development | $34.2M | $34.4M | $37.0M | $35.4M | $26.6M | $18.6M | $15.0M |
| Operating expenses | — | $131.9M | $138.2M | $135.8M | $112.0M | $65.7M | $57.6M |
| Operating income | −$70.9M | −$66.6M | −$74.8M | −$87.8M | −$71.5M | −$37.4M | — |
| Net income | −$79.0M | −$62.5M | −$79.0M | −$87.4M | −$73.7M | −$39.3M | −$33.8M |
| Basic EPSper diluted share | -$1.17 | -$0.95 | -$1.22 | -$1.36 | -$1.33 | -$0.93 | — |
| Diluted EPSper diluted share | -$1.17 | -$0.95 | -$1.22 | -$1.36 | -$1.33 | -$0.93 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Camblong JurgiChief Executive Officer | SellOrdinary Shares | 31.9K | $5.84 | $186.5K | 3.60M |
| Jun 26, 2026Form 4 · 10b5-1 | Camblong JurgiChief Executive Officer | SellOrdinary Shares | 18.1K | $5.73 | $103.9K | 3.60M |
| Jun 25, 2026Form 4 · 10b5-1 | Camblong JurgiChief Executive Officer | SellOrdinary Shares | 1.4K | $5.70 | $7.8K | 3.62M |
| Jun 25, 2026Form 4 · 10b5-1 | Verma AbhimanyuChief Technology Officer | SellOrdinary Shares | 6.9K | $5.51 | $38.3K | 197.5K |
| Jun 25, 2026Form 4 · 10b5-1 | Menu PhilippeChief Medical Officer | SellOrdinary Shares | 5.0K | $5.50 | $27.5K | 240.8K |